Street Calls of the Week
Ascendis Pharma (NASDAQ:ASND) A/S, a biopharmaceutical company focused on developing innovative therapies for rare endocrine disorders, has garnered significant attention from analysts due to its strong product launches and promising pipeline. Currently trading at $174.18, near its 52-week high of $183, the company has demonstrated impressive momentum with a 24.17% return over the past six months, according to InvestingPro data. The company’s flagship product, Yorvipath, for the treatment of hypoparathyroidism, has exceeded expectations since its launch, driving optimism about Ascendis’ future prospects.
Yorvipath Launch and Market Potential
Yorvipath’s commercial success has been a key driver of Ascendis’ recent performance. In the first quarter of 2025, Yorvipath sales reached €44.7 million, significantly surpassing the consensus estimate of €31.1 million. This strong performance has been attributed to rapid market adoption and a broadening prescriber base.
Analysts note that the patient script count for Yorvipath nearly doubled in approximately two months, indicating robust demand and market penetration. Positive feedback from physicians highlights the drug’s simplified dosing regimen and potential renal protection benefits as key factors driving adoption.
The market potential for Yorvipath appears substantial. Analysts estimate there are approximately 90,000 patients with hypoparathyroidism in the United States alone. Some projections suggest Yorvipath could become a €3 billion drug, surpassing the current consensus estimate of €2 billion. This optimistic outlook is based on Ascendis’ first-mover advantage in a significant market with limited competition.
Pipeline and Product Portfolio
Beyond Yorvipath, Ascendis’ pipeline shows promise, particularly in the treatment of achondroplasia. The company’s TransCon CNP product candidate has demonstrated encouraging results in clinical trials. Interim data from the Phase 2 COACH trial, evaluating a combination therapy of TransCon CNP and human growth hormone (hGH) in achondroplasia patients, showed significant improvements in growth velocity.
Analysts predict that this combination therapy could potentially demonstrate the best-in-disease increase in annual growth velocity at the 6-month mark. However, some caution that regulatory approval in the United States may face challenges due to historical issues with human growth hormone treatments.
Ascendis’ growth hormone product, Skytrofa, has shown mixed performance. While Q1 2025 sales of €51 million fell slightly below the consensus estimate of €62 million, analysts attribute this to seasonal factors and expect improvement in subsequent quarters. Skytrofa is projected to generate up to €500 million in revenue with potential label expansions.
Financial Outlook
Ascendis Pharma’s financial prospects appear promising, with analysts projecting significant revenue growth in the coming years. Estimates suggest revenue could increase from €363.6 million in 2024 to €1.72 billion by 2027. While the company currently operates at a loss with an EBITDA of -$355.76 million in the last twelve months, it maintains a strong gross margin of 85.3%. InvestingPro analysis reveals the company operates with moderate debt levels, and analysts expect revenue growth of 68% in FY2025. Moreover, the company is expected to achieve profitability, with earnings per share (EPS) turning positive by 2026.
Despite the positive revenue outlook, some analysts have adjusted their near-term EPS forecasts due to higher than expected operational expenses. However, these expenses are anticipated to normalize in subsequent years as the company scales its operations.
Competitive Landscape
While Ascendis Pharma enjoys a first-mover advantage in some of its key markets, the company faces competition from other pharmaceutical firms. In the hypoparathyroidism space, companies like AstraZeneca (NASDAQ:AZN) and MBX Biosciences are developing alternative treatments. However, analysts suggest that these competitors may lack differentiation or are significantly behind Ascendis in terms of development timelines.
In the achondroplasia market, BioMarin (BMRN) and BridgeBio (BBIO) are notable competitors. BioMarin’s Voxzogo is currently the market leader, but analysts believe Ascendis’ combination therapy could potentially outperform it in terms of efficacy and convenience.
Bear Case
Can Ascendis sustain its early growth momentum for Yorvipath?
While Yorvipath’s launch has been impressive, sustaining this growth trajectory may prove challenging. The initial surge in prescriptions could represent pent-up demand from severe patients eager for new treatment options. As this initial patient pool is addressed, maintaining the same growth rate may become more difficult. Additionally, the company will need to navigate the transition from early adopters to broader market acceptance, which often requires different strategies and resources.
What reimbursement challenges could impact adoption of Ascendis’ therapies?
Reimbursement remains a critical factor in the adoption of new therapies, particularly for high-cost treatments. Yorvipath’s significant price difference compared to conventional therapies may pose challenges in securing favorable reimbursement terms, especially for moderate patients. Payers may require substantial evidence of long-term benefits and cost-effectiveness to justify coverage. Moreover, potential restrictions on off-label use for patients with serum calcium levels outside the indicated range could limit the addressable market.
Bull Case
How much additional market potential exists for Ascendis’ key products?
Ascendis Pharma’s key products, particularly Yorvipath and its achondroplasia treatment, may have substantial untapped market potential. For Yorvipath, the initial focus has been on severe hypoparathyroidism patients, estimated at about 15% of the total patient population. If the drug demonstrates long-term benefits over conventional therapy, it could gradually expand its use to moderate patients, significantly increasing its market reach. In achondroplasia, success in ongoing trials could position Ascendis’ treatment as a best-in-class option, potentially capturing a larger share of the market than currently projected.
What long-term growth drivers could propel Ascendis beyond current projections?
Several factors could drive Ascendis’ growth beyond current expectations. The company’s TransCon technology platform has applications beyond its current focus areas, as evidenced by the recent partnership with Novo Nordisk (NYSE:NVO) in obesity treatment. With a highly favorable analyst consensus rating of 1.25 (where 1 is Strong Buy), Wall Street remains optimistic about the company’s prospects. For deeper insights into Ascendis’ growth potential and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers what really matters about this and 1,400+ other top stocks through intuitive visuals and expert analysis. Success in this collaboration could open up a massive market opportunity. Additionally, Ascendis’ pipeline includes promising developments in areas like X-linked hypophosphatemia (XLH), which could provide new revenue streams. The company’s attractiveness as an M&A target, as noted by some analysts, could also lead to value creation through strategic partnerships or acquisition premiums.
SWOT Analysis
Strengths:
- Strong product launches, particularly Yorvipath
- Innovative TransCon technology platform
- First-mover advantage in key markets
- Promising pipeline with multiple potential growth drivers
Weaknesses:
- Currently unprofitable, with high operational expenses
- Dependence on success of key products for near-term growth
- Limited commercial experience compared to larger competitors
Opportunities:
- Large addressable markets in rare endocrine disorders
- Potential for label expansions and new indications
- Strategic partnerships and M&A potential
- Expansion into broader therapeutic areas (e.g., obesity)
Threats:
- Competitive landscape with well-resourced rivals
- Regulatory challenges, particularly for combination therapies
- Reimbursement hurdles for high-cost treatments
- Potential for clinical trial setbacks or safety concerns
Analysts Targets
Morgan Stanley (NYSE:MS): $250 (July 2nd, 2025)
RBC Capital Markets: $210 (May 2nd, 2025)
Cantor Fitzgerald: $200 (May 12th, 2025)
RBC Capital Markets: $205 (April 16th, 2025)
Cantor Fitzgerald: $200 (February 25th, 2025)
Cantor Fitzgerald: $170 (February 11th, 2025)
Evercore ISI: $220 (December 20th, 2024)
This analysis is based on information available up to July 6, 2025.
InvestingPro: Smarter Decisions, Better Returns
Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on ASND. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore ASND’s full potential at InvestingPro.
Should you invest in ASND right now? Consider this first:
Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if ASND is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.
To evaluate ASND further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if ASND appears on our undervalued or overvalued stock lists.
These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.